BioCurity is developing the only drug product to prevent side effects for patients undergoing radiation therapy. As Jim Sergi, BioCurity’s clinical development lead, stated, “We are excited to have the opportunity to leverage our oncology experience and expertise to advance the commercial development of BioCurity’s lead drug compound for patients undergoing radiation therapy. BioCurity offers the potential to prevent the often-devastating side effects associated with radiation therapy,” - President CSSi LifeSciences. 

KEYS TO THE BIOCURITY SUCCESS:

  • Attention to de-risking the drug development process and exit opportunities while meeting important milestones
  • Potential fast track and orphan drug designation
  • Relatively low cost of manufacturing the drug
  • Issued patents to support products under development in the United States and Internationally.
  • Positive pre-clinical results in lung, head and neck, breast, and other cancers
  • Multiple value inflection points over the next 18-24 months
  • Experienced business management team in United States and International Transactions

WHY BIOCURITY? INVESTING IN THE GLOBAL SUPPORTIVE CARE MARKET

“BioCurity is a global leader in drug development using nanoparticles to mitigate the side effects associated with radiation therapy. The short and long-term side effects from radiation therapy can impair a cancer patient's medical treatment plan and can leave cancer survivors with permanent adverse conditions," said Dr. Baker, PhD BioCurity’s Scientific Co-Founder.
The cancer supportive care market is poised to reach $23B by 2026 and is driven by the growing prevalence of cancer cases.

SUCCESS IN THE GLOBAL CARE ONCOLOGY MARKET

  • With a topical and IV formulation the drugs being developed can be used on multiple cancers on skin and internal tissue
  • Radiation side effects affect millions of cancer patients globally as 6 million new cancer patients receive radiation every year
  • Core team has over 150 years of combined experience in international markets, drug development and investment banking
  • Outstanding Scientific and Medical Advisory Group assembled
Print Print | Sitemap
© 2021 BioCurity Pharmaceuticals Inc. All Rights Reserved.